Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations.

Döhner, Hartmut; DiNardo, Courtney D; Wei, Andrew H; Löwenberg, Bob; Appelbaum, Frederick; Craddock, Charles; Dombret, Hervé; Ebert, Benjamin L; Fenaux, Pierre; Godley, Lucy A; Hasserjian, Robert P; Larson, Richard A; Levine, Ross L; Miyazaki, Yasushi; Niederwieser, Dietger; Ossenkoppele, Gert J; Röllig, Christoph; Sierra, Jorge; Stein, Eytan M; Tallman, Martin S; Tien, Hwei-Fang; Wang, Jianxiang; Wierzbowska, Agnieszka

Döhner, Hartmut; DiNardo, Courtney D; Wei, Andrew H; Löwenberg, Bob; Appelbaum, Frederick; Craddock, Charles; Dombret, Hervé; Ebert, Benjamin L; Fenaux, Pierre; Godley, Lucy A; Hasserjian, Robert P; Larson, Richard A; Levine, Ross L; Miyazaki, Yasushi; Niederwieser, Dietger; Ossenkoppele, Gert J; Röllig, Christoph; Sierra, Jorge; Stein, Eytan M; Tallman, Martin S; Tien, Hwei-Fang; Wang, Jianxiang; Wierzbowska, Agnieszka.

Afiliación

Döhner H; University Hospital Ulm, Ulm, Germany.
DiNardo CD; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.
Wei AH; Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia.
Löwenberg B; Department of Hematology, Erasmus MC, Rotterdam, The Netherlands, Rotterdam, Netherlands.
Appelbaum F; Fred Hutchinson Cancer Center, Seattle, WA, USA, Seattle, Washington, United States.
Craddock C; University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.
Dombret H; Université Paris Cité, Hôpital Saint-Louis, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France.
Ebert BL; Dana-Farber Cancer Institute, Boston, Massachusetts, United States.
Fenaux P; hôpital St Louis, Paris, PARIS, France.
Godley LA; Northwestern University, Chicago, Illinois, United States.
Hasserjian RP; Massachusetts General Hospital, Boston, Massachusetts, United States.
Larson RA; University of Chicago, Chicago, Illinois, United States.
Levine RL; Memorial Sloan-Kettering Cancer Center, New York, New York, United States.
Miyazaki Y; Atomic Bomb Disease Institute, Ngasaki University, Nagasaki, Japan.
Niederwieser D; University Leipzig, Leipzig, Germany.
Ossenkoppele GJ; Amsterdam UMC, location VUmc, Amsterdam, Netherlands.
Röllig C; Department of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany, Dresden, Germany.
Sierra J; Hospital Santa Creu i Sant Pau, Barcelona, Spain.
Stein EM; Memorial Sloan Kettering Cancer Center, New York, New York, United States.
Tallman MS; Memorial Sloan Kettering Cancer Center, Highland Park, Illinois, United States.
Tien HF; National Taiwan University Hospital, Taipei, Taiwan.
Wang J; State Key Laboratory of Experimental Hematology, National Clinical Research Center of Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
Wierzbowska A; Medical University of Lodz, Lodz, Poland.

Blood ; 2024 Aug 12.

Article en En | MEDLINE | ID: mdl-39133932

ABSTRACT

ABSTRACT

The European LeukemiaNet (ELN) genetic risk classifications were developed based on data from younger adults receiving intensive chemotherapy. Emerging analyses from patients receiving less-intensive therapies prompted a proposal for an ELN genetic risk classification specifically for this patient population.

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Blood Año: 2024 Tipo del documento: Article País de afiliación: Alemania